You are here

Home » Content

115 KANSER HASTASINDA PORT KOMPLİKASYONLARININ DEĞERLENDİRİLMESİ

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
This study was conducted to evaluate complications associated with venous access devices used in long-term therapies in the cancer patients. Methods.- One hundred and fifteen consequtive adult cancer patients in whom a subcutaneous port was inserted were evaluated retrospectively between 1996 and 2004. Results- The total accrued sum of device-days for the 115 ports studied was 62,004 days, the average duration after placement was 539 days (range,8-2348 days), and the median duration was 382 days. Complications were identified in 11 of the 115 patients (9.5%). The average duration of ports in the complication group was 467 days (range, 8-1024 days) and median was 407 days. Complications included thrombosis (n:6; 5.1%) in which in one of the patients the catheter end was found in the right femoral vein instead of right atrium causing deep venous thrombosis, port infection (n:1; 0.8%), pneumothorax (n:1; 0.8%), mediastinal extravasation (n:1; 0.8%), port occlusion (n:1; 0.8%) and breaking of the catheter of the port (n:1; 0.8%). Port removal as a result of the complication was performed in 7 patients. Conclusions.- The insertion technique and maintenance of sterility and safety is very important in long term intravenous access devices used in long term therapies in the cancer patients.
Bookmark/Search this post with
Abstract (Original Language): 
Kanser hastalarının uzun süreli tedavilerin-de kullanılan kalıcı santral venöz portların na-sıl takıldığı ve bakımı, daha sonradan çıkabile-cek komplikasyonlar açısından çok önemlidir. Bu çalışmada santral venöz kateterlerle ilgili çıkabilecek sorunlar ve komplikasyonların de-ğerlendirilmesi amaçlanmıştır. 1996-2004 yıl-ları arasında port takılan 115 kanser hastası ret-rospektif olarak değerlendirilmiştir. 115 hasta-da port süresi toplam 62004 gün, ortalama 539 gün, medyan değeri ise 382 gündür (Min: 8, Max: 2348). Yüzonbeş hastanın 11’inde komp-likasyon görüldü (%9,5). Komplikasyon geli-şen hastalarda portun takılı kaldığı süre ortala-ma 467 gün, medyan ise 407 gündür (Max: 1,024, Min: 8 ). Altı hastada tromboz saptandı (%5.1). Bu hastalardan birinde port ucu sağ at-riumda olmalıyken, sağ femoral vende olduğu için derin ven trombozuna sebep olmuştu ve port çıkartıldı (%0,8). Bir hastada pnömotoraks gelişti (%0.8).1 hastada port koptu (%0,8). Bir hastada enfeksiyon saptandı (%0,8). Bir hasta-da port kullanımı sırasında mediastene ekstra-vazasyon gelişti (%0,8). Bir hastada ise port tıkandığı için çıkartıldı (%0,8). Onbir hastadan toplam yedisinde port çıkarıldı. Çok yaygın olarak kanser hastalarına uygulanmaya başla-nan portların deneyimli kişilerce takılması, ve port bakımının düzenli ve iyi bir şekilde ya-pılması gerekmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-115-kanser-hastasinda-port-komplikasyonlarinin-degerlendirilmesi.pdf
  • 2
71-77
  • Turkish

REFERENCES

References: 

1. Broviac JW; Cole JJ, Scribner BH: Prolonged parenteral nutrition in the home. Surg Gynecol Obstet. 1974; 139: 24-28.
2. Alexander HR, Vascular access and other specialized techniques of drug delivery. 5th ed. DeVita, 5: 556-564.
3. Groeger JS, Lucas AB, Coit D. Venous access in the cancer patients. PPO updates, 1991; 5: 1-14.
4. Groeger JS, Lucas AB, Thaler Hat, et al. Infectious morbidity associated with long term use of venous access devices in patients with cancer. Ann Intern Med, 1993; 119: 1168-74.
5. Muscudere G, Bennett JD, Lee TY, Mackie I, Vanderburgh L. Complications of radiologically placed central venous ports and Hickman catheters in patients with AIDS. Can Assoc Radiol J. 1998; 49: 84-89.
6. Morris SL, Jaques PF, Mauro MA. Radiology assisted placement of implantable subcutanous infusion ports for long term venous access. Radiology, 1992; 184: 149-151.
7. Damascelli B, Patelli G, Frigerio LF, et al. Placement of long term central venous catheters in outpatients: study of 134 patients over 24,596 catheter days. Am J Radiol, 1998; 168: 1235-1239.
8. Lambert ME, Chadwick GA, McMahon A, Scarfe JH: Experience with the Port-a-Cath. Hematol Oncol, 1988; 6: 57-63
9. May GS, Davis C. Percutaneous catheters and totally implantable access systems: A review of reported infection rates. J Intravenous Nurs, 1988; 11: 97-103
10. Poorter RL, Lauw FN, Bemelman WA, et al: Complications of an implantable venous access device (Port-a-Cath=during intermittant continuous infusion of chemotherapy. Eur J Cancer, 1996; 32: 2262-2266
11. Koch HJ, Pietsch M, Krause U, Wilke H, Eigler FW. Implantable vascular access systems: Experience in 1500 patients with totally implanted central venous port systems. World J Surg. 1998; 22: 12-16.
12. Torramade JR, Cienfuegos JA, Hernandez JL, et al. The complications of central venous access systems: a study of 218 patients. Eur J Surg. 1993; 159: 323-327.
13. Raad I, Hana H. Nasocomial infections related to use of intravascular devices inserted for long-term vascular access. In: Mayhall CG,ed. Hospital epidemiology and infection control. 2nd ed. Philadelphia:Lippincott Williams &Wilkins: 1999; 165-172.
14. Wheat LJ. Fungal infections in the immunocompromised host. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. 3rd ed. New York: Plenum Medical Book Company: 1994; 211-232.
15. Schwarz RE, Groeger JS, Coit DG: Subcutanously implanted central venous access devices in cancer patients: a prospective analysis. Cancer, 1997; 79: 1635-1640.
16. Hempsey SJ, Young JE, Alcock SR, Stack BH. Needle change preferences and rate of infection in cystic fibrosis adult with a Port-a-Cath device insitu (abstract). Thorax 1998; 53(Suppl14): 62
17. Ballarini C, Intra N, Piani-Ceratti A, et al. Complications of subcutaneous infusion port in the general oncology population. Oncology, 1999; 56: 97-102.
18. Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol, 1995; 13: 233-238.
19. Lokich JL, Bothe A, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol, 1985; 3: 710-717
20. Brincker H, Saeter G. Fifty-five patient years experience with a totally implanted system for intravenous chemotherapy. Cancer, 1986; 57: 1124-1129
21. Behesti MV, Protzer WR, Tomlinson TL, et al. Long term results of radiologic placement of a central vein access device. Am J Radiol, 1998; 170: 731-734
22. Kaufman JA, Salamipour H, Geller SC, et al. Long term outcome of radiologicaly placed arm ports. Radiology, 1996; 201: 725-730
23. Cassidy FP, Zajko AB, Bron KM, et al. Noninfectious complications of long term central venous catheters: Radiologic evaluation management. Am J Radiol, 1987; 149: 671-675.
24. Anderson AJ. Krawnow SH, Boyer MW, et al. Hickman catheter clots. A common occurence despite daily heparin flushing. Cancer treat Rep, 1987; 71: 651-653
25. Lazarus HM, Lowder JN, Herzig RH. Occlusion and infection in Broviac catheters during intensive cancer therapu. Cancer, 1983; 52: 2342-2348.
26. Bozkurt AK, Uzel B, Akman C, Özgüroğlu M, Mandel NM: Intrathoracic extravasation of antineoplastic agents. Am J Clin Oncol, 2003; 26: 121-123.
27. Luciani A, Clement O, Halimi P, et al. Catheter related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology, 2001; 220: 655
28. Bodner LJ, Nosher LJ, Patel KM, et al. Peripheral venous access ports: outcomes analysis in 109 patients. Cardiovasc Intervent Radiol. 2000; 23: 187.

Thank you for copying data from http://www.arastirmax.com